Track topics on Twitter Track topics that are important to you
Gracell, a Suzhou-Shanghai biotech, announced positive early results of its first-in-class FasT CAR-19 investigational cell gene therapy: in 24 patients, 23 (95.8%) achieved complete remission and 21 (87.5%) showed undetectable minimal residual disease (uMRD). All of the patients had relapsed/refractory B-ALL leukemia. Gracell's FasT CAR therapy reduces preparation time of the T-cells from two weeks to one day, lowering the cost. The results were announced during the CAR-TCR Summit currently being held in Boston. More details....
Share this with colleagues:
Original Article: Gracell Reports Positive Results from FasT CAR-19 Cell Gene TherapyNEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...